evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 10 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 20%Moderate 6 · 60%High 2 · 20%

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in any thromboembolic event compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in major bleeding compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in clinically relevant non‐major bleeding compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo

Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review